PURPOSE: A significant barrier to efficient antibiotic management of infection is that the standard diagnostic methodologies do not provide results at the point of care. The delays between sample collection and bacterial culture and antibiotic susceptibility reporting have led to empirical use of antibiotics, contributing to the emergence of drug resistant pathogens. As a key step toward the development of a point of care device for determining the antibiotic susceptibility of urinary tract pathogens, we report on a biosensor based antimicrobial susceptibility test. MATERIALS AND METHODS: For assay development bacteria were cultured with or without antibiotics, and growth was quantitated by determining viable counts and electrochemical biosensor measurement of bacterial 16S rRNA. To determine antibiotic susceptibility directly from patient samples, urine was cultured on antibiotic plates for 2.5 hours and growth was determined by electrochemical measurement of bacterial 16S rRNA. For assay validation 252 urine samples were collected from patients at the Spinal Cord Injury Service at Veterans Affairs Palo Alto Health Care System. The biosensor based antimicrobial susceptibility test was completed for samples containing gram-negative organisms. Pathogen identification and antibiotic susceptibility results were compared between our assay and standard microbiological analysis. RESULTS: A direct biosensor quantitation of bacterial 16S rRNA can be used to monitor bacterial growth for a biosensor based antimicrobial susceptibility test. Clinical validation of a biosensor based antimicrobial susceptibility test with patient urine samples demonstrated that this test was 94% accurate in 368 pathogen-antibiotic tests compared to standard microbiological analysis. CONCLUSIONS: This biosensor based antimicrobial susceptibility test, in concert with our previously described pathogen identification assay, can provide culture and susceptibility information directly from a urine sample within 3.5 hours.
PURPOSE: A significant barrier to efficient antibiotic management of infection is that the standard diagnostic methodologies do not provide results at the point of care. The delays between sample collection and bacterial culture and antibiotic susceptibility reporting have led to empirical use of antibiotics, contributing to the emergence of drug resistant pathogens. As a key step toward the development of a point of care device for determining the antibiotic susceptibility of urinary tract pathogens, we report on a biosensor based antimicrobial susceptibility test. MATERIALS AND METHODS: For assay development bacteria were cultured with or without antibiotics, and growth was quantitated by determining viable counts and electrochemical biosensor measurement of bacterial 16S rRNA. To determine antibiotic susceptibility directly from patient samples, urine was cultured on antibiotic plates for 2.5 hours and growth was determined by electrochemical measurement of bacterial 16S rRNA. For assay validation 252 urine samples were collected from patients at the Spinal Cord Injury Service at Veterans Affairs Palo Alto Health Care System. The biosensor based antimicrobial susceptibility test was completed for samples containing gram-negative organisms. Pathogen identification and antibiotic susceptibility results were compared between our assay and standard microbiological analysis. RESULTS: A direct biosensor quantitation of bacterial 16S rRNA can be used to monitor bacterial growth for a biosensor based antimicrobial susceptibility test. Clinical validation of a biosensor based antimicrobial susceptibility test with patient urine samples demonstrated that this test was 94% accurate in 368 pathogen-antibiotic tests compared to standard microbiological analysis. CONCLUSIONS: This biosensor based antimicrobial susceptibility test, in concert with our previously described pathogen identification assay, can provide culture and susceptibility information directly from a urine sample within 3.5 hours.
Authors: Joseph C Liao; Mitra Mastali; Vincent Gau; Marc A Suchard; Annette K Møller; David A Bruckner; Jane T Babbitt; Yang Li; Jeffrey Gornbein; Elliot M Landaw; Edward R B McCabe; Bernard M Churchill; David A Haake Journal: J Clin Microbiol Date: 2006-02 Impact factor: 5.948
Authors: Joseph C Liao; Mitra Mastali; Yang Li; Vincent Gau; Marc A Suchard; Jane Babbitt; Jeffrey Gornbein; Elliot M Landaw; Edward R B McCabe; Bernard M Churchill; David A Haake Journal: J Mol Diagn Date: 2007-04 Impact factor: 5.568
Authors: Nathan G Schoepp; Eugenia M Khorosheva; Travis S Schlappi; Matthew S Curtis; Romney M Humphries; Janet A Hindler; Rustem F Ismagilov Journal: Angew Chem Int Ed Engl Date: 2016-06-30 Impact factor: 15.336
Authors: Angela M Caliendo; David N Gilbert; Christine C Ginocchio; Kimberly E Hanson; Larissa May; Thomas C Quinn; Fred C Tenover; David Alland; Anne J Blaschke; Robert A Bonomo; Karen C Carroll; Mary Jane Ferraro; Lisa R Hirschhorn; W Patrick Joseph; Tobi Karchmer; Ann T MacIntyre; L Barth Reller; Audrey F Jackson Journal: Clin Infect Dis Date: 2013-12 Impact factor: 9.079
Authors: Anja Mezger; Erik Gullberg; Jenny Göransson; Anna Zorzet; David Herthnek; Eva Tano; Mats Nilsson; Dan I Andersson Journal: J Clin Microbiol Date: 2014-11-19 Impact factor: 5.948
Authors: Hui Li; Peter Torab; Kathleen E Mach; Christine Surrette; Matthew R England; David W Craft; Neal J Thomas; Joseph C Liao; Chris Puleo; Pak Kin Wong Journal: Proc Natl Acad Sci U S A Date: 2019-05-08 Impact factor: 11.205
Authors: Marlene Fredborg; Klaus R Andersen; Erik Jørgensen; Aida Droce; Tom Olesen; Bent B Jensen; Flemming S Rosenvinge; Teis E Sondergaard Journal: J Clin Microbiol Date: 2013-04-17 Impact factor: 5.948
Authors: Hsiang Chia Chen; Chia Hsiang Chen; Vincent Gau; Donna D Zhang; Joseph C Liao; Fei-Yue Wang; Pak Kin Wong Journal: PLoS One Date: 2010-11-11 Impact factor: 3.240